鄰近類別 圖書 [1/1] 專利 [0/7] 類別統計 近3年內發表的文件:7(15.91%) 含全文筆數:44(100.00%) 文件下載次數統計 下載大於0次:44(100.00%) 下載大於100次:42(95.45%) 檔案下載總次數:22526(98.31%) 最後更新時間: 2024-12-01 04:07 上傳排行 資料載入中..... 下載排行 資料載入中..... 最近上傳 Enhanced production of recombinant ... The stability and immunogenicity of... Propagation and immunological chara... Separation and purification of high... The uncoating of EV71 in mature lat... Intranasal immunization with zika v... Novel strategies for the developmen... Recombinant hemagglutinin produced ... Highly immunogenic influenza virus-... Glycan-masking hemagglutinin antige...

跳至: (選擇年份) 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 1993 1992 1991 1990 1985 1980 1975 1970 1960 1950 (選擇月份) January February March April May June July August September October November December 或輸入年份:

由新到舊排序 由最舊的開始

顯示項目1-44 / 44. (共1頁) 1  每頁顯示[10|25|50]項目

日期	題名	關聯
2024-10	Enhanced production of recombinant coxsackievirus A16 using a serum-free HEK293A suspension culture system for bivalent enterovirus vaccine development	Vaccine: X. 2024 Oct;20:Article number 100559.
2023-12	The stability and immunogenicity of formalin-inactivated Enterovirus A71 whole virion vaccine after ten years of low temperature storage	Journal of Microbiology, Immunology and Infection. 2023 Dec;56(6):1121-1128.
2023-03-24	Propagation and immunological characterization of coxsackievirus A10 in a serum-free HEK293A cell culture system	Virus Research. 2023 Mar 24;329:Article number 199101.
2022-09-15	The uncoating of EV71 in mature late endosomes requires CD-M6PR	Biology Open. 2022 Sep 15;11(9):Article number bio059469.
2022-09-13	Separation and purification of highly infectious enterovirus A71 particles using a strong anion-exchange column	Journal of Chromatography A. 2022 Sep 13;1680:Article number 463427.
2022-05-08	Intranasal immunization with zika virus envelope domain III-flagellin fusion protein elicits systemic and mucosal immune responses and protection against subcutaneous and intravaginal virus challenges	Pharmaceutics. 2022 May 8;14(5):Article number 1014.
2022-01	Novel strategies for the development of hand, foot, and mouth disease vaccines and antiviral therapies	Expert Opinion on Drug Discovery. 2022 Jan;17(1):27-39.
2019-11	Recombinant hemagglutinin produced from Chinese Hamster Ovary (CHO) stable cell clones and a PELC/CpG combination adjuvant for H7N9 subunit vaccine development	Vaccine. 2019 Nov;37(47):6933-6941.
2019-04	Highly immunogenic influenza virus-like particles containing B-cell-activating factor (BAFF) for multi-subtype vaccine development	Antiviral Research. 2019 Apr;164:12-22.
2019-03	Glycan-masking hemagglutinin antigens from stable CHO cell clones for H5N1 avian influenza vaccine development	Biotechnology and Bioengineering. 2019 Mar;116(3):598-609.
2018-08-22	Recent development of enterovirus a vaccine candidates for the prevention of hand, foot, and mouth disease	Expert Review of Vaccines. 2018 Aug 22;17(9):819-831.
2018-08	Maternal immunization with a recombinant adenovirus-expressing fusion protein protects neonatal cotton rats from respiratory syncytia virus infection by transferring antibodies via breast milk and placenta	Virology. 2018 Aug;521:181-189.
2018-06-04	Mutations in VP1 and 5′-UTR affect enterovirus 71 virulence [Erratum: Scientific Reports. 2018 Apr 27;8(1):Article number 6688.]	Scientific Reports. 2018 Jun 4;8:Article number 8744.
2018-05	Enhancing enterovirus A71 vaccine production yield by microcarrier profusion bioreactor culture	Vaccine. 2018 May;36(22):3134-3139.
2018-04-27	Mutations in VP1 and 5′-UTR affect enterovirus 71 virulence	Scientific Reports. 2018 Apr 27;8(1):Article number 6688.
2016-09	Multi-subtype influenza virus-like particles incorporated with flagellin and granulocyte-macrophage colony-stimulating factor for vaccine design	Antiviral Research. 2016 Sep;133:110-118.
2016-08	Development of a full-length cDNA-derived enterovirus A71 vaccine candidate using reverse genetics technology	Antiviral Research. 2016 Aug;132:225-232.
2016-06	Immunogenicity of an adeno-vector vaccine expressing the F protein of a respiratory syncytial virus manufactured from serum-free suspension culture	Antiviral Research. 2016 Jun;130:27-35.
2016-05	Immunological and biochemical characterizations of Coxsackievirus A6 and A10 viral particles	Antiviral Research. 2016 May;129:58-66.
2015-04	Recombinant adeno-vaccine expressing Enterovirus 71-like particles against hand, foot, and mouth disease	PLoS Neglected Tropical Diseases. 2015 Apr;9(4):Article number e0003692.
2015-03	Review of enterovirus 71 vaccines	Clinical Infectious Diseases. 2015 Mar;60(5):797-803.
2014-10	Prospect and challenges for the development of multivalent vaccines against hand, foot and mouth diseases	Vaccine. 2014 Oct;32(47):6177-6182.
2014-09-08	Long-term immunogenicity studies of formalin-inactivated Enterovirus 71 whole-virion vaccine in macaques	PLoS ONE. 2014 Sep 8;9(9):Article number e106756.
2014-08-27	Delivery of human EV71 receptors by adeno-associated virus increases EV71 infection-induced local inflammation in adult mice	BioMed Research International. 2014 Aug 27;2014:Article number 878139.
2014-07-30	Toll-like receptor 9-mediated protection of enterovirus 71 infection in mice is due to the release of danger-associated molecular patterns	Journal of Virology. 2014 Jul 30;88(20):11658-11670.
2014-06-11	Immunogenicity studies of bivalent Inactivated virions of EV71/CVA16 formulated with submicron emulsion systems	Biomed Research International. 2014 Jun 11;2014:Article number 670506.
2013-12	Monoclonal antibodies for diagnosis of enterovirus 71	Monoclonal Antibodies in Immunodiagnosis and Immunotherapy. 2013 Dec;32(6):386-394.
2013-11-21	Formalin-inactivated EV71 vaccine candidate induced cross-neutralizing antibody against subgenotypes B1, B4, B5 and C4A in adult volunteers	PLoS ONE. 2013 Nov 21;8(11):Article number e79783.
2013-11	Formulation and immunological evaluation of a trivalent vaccine comprising emulsified submicron particles and inactivated virions of H5N1/EV71/JEV	Human Vaccines and Immunotherapeutics. 2013 Nov ;9(11):2378-2385.
2013-10-02	Heat Shock protein 90: Role in enterovirus 71 entry and assembly and potential target for therapy	PLoS ONE. 2013 Oct 2;8(10):Article number e77133.
2013-08	Caveolar endocytosis is required for human PSGL-1-mediated enterovirus 71 infection	Journal of Virology. 2013 Aug;7(16):9064-9076.
2013-07-30	Protective efficacy of VP1-specific neutralizing antibody associated with a reduction of viral load and pro-inflammatory cytokines in human SCARB2-transgenic mice	PLoS ONE. 2013 Jul 30;8(7):Article number e69858.
2013-05	A Phase I, randomized, open-label study to evaluate the safety and immunogenicity of an enterovirus 71 vaccine	Vaccine. 2013 May;31(20):2471-2476.
2013-02-25	Human SCARB2 transgenic mice as an infectious animal model for Enterovirus 71	PLoS ONE. 2013 Feb 25;8(2):Article number e57591.
2012-12	Production of EV71 vaccine candidates	Human Vaccine Immunotherapy. 2012 Dec;8(12):1775-1783.
2012-11-30	Immunological and biochemical characterization of Coxsackie Virus A16 viral particles	PLoS ONE. 2012 Nov 30;7(11):Article number e49973.
2012-09	Immunological evaluation and comparison of different EV71 vaccine candidates	Clinical and Developmental Immunology. 2012 Sep;2012:Article ID 831282.
2012-04	Pilot scale production of highly efficacious and stable enterovirus 71 vaccine candidates	PLoS ONE. 2012 Apr;7(4):Article number e34834.
2012-01	Human SCARB2-Mediated entry and endocytosis of EV71	PLoS ONE. 2012 Jan;7(1):Article number e30507.
2012-01	Selection and characterization of vaccine strain for Enterovirus 71 vaccine development	Vaccine. 2012 Jan;30(4):703-711.
2011-09	Development of a quantitative enzyme linked immunosorbent assay for monitoring the Enterovirus 71 vaccine manufacturing process	Journal of Virological Methods. 2011 Sep;176(1-2):60-68.
2011-06	Identification and characterization of a cross-neutralization epitope of Enterovirus 71	Vaccine. 2011 Jun;29(26):4362-4372.
2011-05	Purification and characterization of enterovirus 71 viral particles produced from vero cells grown in a serum-free microcarrier bioreactor system	PLoS ONE. 2011 May;6(5):Article number e20005.
2011-05	Generation of murine monoclonal antibodies which cross-neutralize human enterovirus genogroup B isolates	Journal of Virological Methods. 2011 May;173(2):189-195.

顯示項目1-44 / 44. (共1頁) 1  每頁顯示[10|25|50]項目